Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.46 |
| ▸ | HCK | P08631 | 15/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17017630 | 1.00 | MAPK14 (0.46) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL17004776 | 0.90 | MAPK14 (0.48) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL29711928 | 0.89 | MAPK14 (0.45) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL17017622 | 0.89 | SRC (0.47) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL17017694 | 0.87 | MAPK14 (0.48) | MAPK14HCKMAPK12SRCGSK3A | |
| Maleic Acid SCHEMBL29711864 | 0.85 | MAPK14 (0.42) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL17018876 | 0.83 | MAPK14 (0.39) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL31086780 | 0.83 | MAPK14 (0.44) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL17008543 | 0.83 | MAPK14 (0.45) | MAPK14HCKMAPK12SRCGSK3A | |
| SCHEMBL28573504 | 0.82 | HCK (0.38) | MAPK14HCKMAPK12SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634406-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2023-04-25 | — | — | US | disclosed |
| CN-110522731-B | Aromatic heterocycles as anti-inflammatory compounds | 瑞斯比维特有限公司 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634406-B2 | Inhibitor of p38 MAP kinase | MAPK1, MAPKAPK2, MAPK10 | MAPK14 9/4885HCK 812/4885MAPK12 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.